Tag - OGEN

Feature

Oragenics developing novel therapeutics using synthetic bacteria

By Abby Hardy Oragenics (NYSE American: OGEN) is leveraging its synthetic biology platforms to address two significant unmet medical needs: oral mucositis (OM) and multi drug-resistant (MDR) bacterial infections...

May 28, 2019

Developments

Oragenics enrolls 80 patients in Phase 2 oral mucositis trial

Oragenics (NYSE American:OGEN) has enrolled more than 80 patients in its Phase 2 trial of AG013 for the treatment of oral mucositis (OM). The company also reported that the WHO provided AG013 with the generic name...

May 21, 2019

Tag - OGEN

Oragenics developing novel therapeutics using synthetic bacteria

Oragenics enrolls 80 patients in Phase 2 oral mucositis trial

General

More